Cidara touts 'positive' PhII trial data for antifungal, shares yo-yo on the news
This time last year, Cidara $CDTX was reporting a flop in the clinic for its lead drug, an antifungal that failed to impress in Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
